[Topical inhibition of angiogenesis at the cornea. Safety and efficacy].
BACKGROUND
The efficacy and safety of novel topical inhibitors of corneal neovascularisation will be discussed.


METHODS
A literature review after a PUBMED search and own clinical and experimental results are presented.


RESULTS
The off-label use of Avastin eye drops and GS101 eye drops against insulin receptor substrate (IRS)-1, which have been tested in phase II trial, both seem to be relatively efficient and safe ways to inhibit progressive corneal neovascularisation. Other VEGF antagonists, such as ranibizumab and pegaptanib eye drops also inhibit corneal neovascularisation.


CONCLUSIONS
Avastin and GS101 eye drops are the first specific angiogenesis inhibitors for topical inhibition of corneal angiogenesis available for clinical use.
Regenfuss
B
B
Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen
Bock
F
F
Bachmann
B
B
König
Y
Y
Hos
D
D
Parthasarathy
A
A
Cursiefen
C
C
D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy*; D006801:Humans; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D000069579:Ranibizumab; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D009883:Ophthalmic Solutions; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab